Oncology Based In-Vivo CRO Market Report by Indication (Blood Cancer, Solid Tumors, and Others), Model (Syngeneic, Xenograft, Patient Derived Xenograft (PDX), and Others), Application (Hospitals, Rehabilitation Centers), and Region 2024-2032
세계의 종양학 기반 In-Vivo CRO 시장 규모는 2023년 12억 달러에 달했습니다. 앞으로 IMARC Group은 2024년부터 2032년까지 6.9%의 복합 연간 성장률(CAGR)을 보일 전망이며, 2032년까지 시장은 23억 달러에 달할 것으로 예측했습니다.
종양학은 생검, 내시경 검사, X선 검사, 컴퓨터 단층촬영(CT) 스캔, 자기공명영상(MRI) 스캔, 양전자방사단층촬영(PET) 스캔, 초음파검사 등을 이용하여 암 연구, 진단 및 치료 의학의 한 분야를 말합니다. 호르몬요법, 면역요법, 방사선요법, 경구요법을 환자에게 제공하여 암의 부작용을 견디고 완화시킵니다. 현재 암치료를 위한 CRO(의약품개발업무수탁기관)에 의한 여러 임상시험약의 연구개발에 의해 종양학 기반 In-Vivo CRO 수요가 세계적으로 증가하고 있습니다.
종양학 기반 In-Vivo CRO 시장 동향 :
세계의 암 이환율 증가는 시장을 견인하는 중요한 요인 중 하나입니다. 또한 세계의 각국의 정부는 R&D 활동에 대규모 투자를 하고 있습니다. 이에 더해 의약품개발업무수탁기관(CRO)에 의한 암치료에 관한 전문지식의 향상이 시장의 성장을 뒷받침하고 있습니다. 또한, 데옥시리보 핵산(DNA)을 조작하여 생물의 특성을 변화시키는 유전자 공학의 기술 혁신도 증가하고 있습니다. 이것은 세포의 증식, 성장, 분화를 제어하기 위한 암 유전자 연구에 대한 주목의 고조와 함께 시장에 플러스의 영향을 주고 있습니다. 이 외에도 의약품의 광범위한 가용성과 건강 관리 산업의 확대는 종양학 기반의 생체 내 CRO 수요를 세계적으로 자극하고 있습니다. 이와는 별도로 위탁연구기관(CRO)이 자체 조사와 비교하여 제공하는 비용 효율성은 업계 투자자들에게 유리한 성장 기회를 제공합니다. 게다가, 헬스케어 업계에서는 암 환자의 안전성을 확보하기 위해서 원격 의료나 가상 임상시험의 채용이 증가하고 있습니다. 이는 시장 성장을 뒷받침할 것으로 예상됩니다.
이 보고서에서 다루는 주요 질문
- 2023년 세계의 종양학 기반 In-Vivo CRO 시장 규모는?
- 2024-2032년 세계의 종양학 기반 In-Vivo CRO 시장의 예상 성장률은?
- 세계의 종양학 기반 In-Vivo CRO 시장을 견인하는 주요 요인은?
- 세계의 종양학 기반 In-Vivo CRO 시장에 대한 COVID-19의 영향은?
- 세계의 종양학 기반 In-Vivo CRO 시장의 적응증별 내역은?
- 세계의 종양학 기반 In-Vivo CRO 시장의 주요 지역은?
- 세계의 종양학 기반 In-Vivo CRO 시장의 주요 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 종양학 기반 In-Vivo CRO 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 적응증별
제7장 시장 분석 : 모델별
- 동계
- 이종이식
- 환자 유래 이종이식(PDX)
- 기타
제8장 시장 분석 : 용도별
제9장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Champions Oncology Inc.
- Charles River Laboratories International Inc.
- Crown Bioscience Inc.
- Eurofins Scientific
- Evotec SE
- ICON Plc
- Labcorp Drug Development(Laboratory Corporation of America Holdings)
- Living Tumor Laboratory
- Taconic Biosciences Inc.
- The Jackson Laboratory
- WuXi AppTec
- Xentech
BJH
The global oncology based in-vivo CRO market size reached US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.9% during 2024-2032.
Oncology refers to a branch of medicine that studies, diagnoses, and treats cancer using biopsy, endoscopy, X-ray, computed tomography (CT) scanning, magnetic resonance imaging (MRI), positron emission tomography (PET) scanning, and ultrasound. It offers hormonal therapy, immunotherapy, radiotherapy, and oral therapies to patients for tolerating and easing the side effects of cancer. At present, there is a rise in the demand for oncology based in-vivo CRO across the globe due to the development of several investigational compounds by contract research organizations (CROs) for treating cancer.
Oncology Based In-Vivo CRO Market Trends:
The growing prevalence of cancer around the world represents one of the key factors driving the market. Moreover, governments of several countries across the globe are extensively investing in research and development (R&D) activities. This, along with the rising expertise in cancer treatment by contract research organizations (CROs), is propelling the growth of the market. In addition, there is an increase in the innovation of genetic engineering for manipulating deoxyribonucleic acid (DNA) and altering the characteristics of organisms. This, coupled with the growing focus on oncogene study to regulate proliferation, growth, and differentiation of cells, is positively influencing the market. Besides this, the wide availability of medicines, along with the expanding healthcare industry, is catalyzing the demand for oncology based in-vivo CRO worldwide. Apart from this, the cost-efficiency offered by contract research organizations (CROs) compared to an in-house study is offering lucrative growth opportunities to industry investors. Additionally, there is an increase in the adoption of telehealth and virtual clinical trials in the healthcare industry for ensuring the safety of cancer patients. This is projected to bolster the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology based in-vivo CRO market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on indication, model and application.
Breakup by Indication:
Blood Cancer
Solid Tumors
Others
Breakup by Model:
Syngeneic
Xenograft
Patient Derived Xenograft (PDX)
Others
Breakup by Application:
Hospitals
Rehabilitation Centers
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec and Xentech.
Key Questions Answered in This Report
- 1. What was the size of the global oncology based in-vivo CRO market in 2023?
- 2. What is the expected growth rate of the global oncology based in-vivo CRO market during 2024-2032?
- 3. What are the key factors driving the global oncology based in-vivo CRO market?
- 4. What has been the impact of COVID-19 on the global oncology based in-vivo CRO market?
- 5. What is the breakup of the global oncology based in-vivo CRO market based on the indication?
- 6. What is the breakup of the global oncology based in-vivo CRO market based on the model?
- 7. What are the key regions in the global oncology based in-vivo CRO market?
- 8. Who are the key players/companies in the global oncology based in-vivo CRO market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Oncology Based In-Vivo CRO Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Indication
- 6.1 Blood Cancer
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Solid Tumors
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Others
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Model
- 7.1 Syngeneic
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Xenograft
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Patient Derived Xenograft (PDX)
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Application
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Rehabilitation Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Champions Oncology Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.2 Charles River Laboratories International Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Crown Bioscience Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Eurofins Scientific
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Evotec SE
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 ICON Plc
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Labcorp Drug Development (Laboratory Corporation of America Holdings)
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 SWOT Analysis
- 14.3.8 Living Tumor Laboratory
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 Taconic Biosciences Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.10 The Jackson Laboratory
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.11 WuXi AppTec
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.12 Xentech
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
